|Mr. Carmelo Marrelli A.C.I.S., B.Com., C.A., C.P.A., CPA, B.Comm., CA||Chief Financial Officer||71.47k||N/A||1971|
|Mr. Michael Frank||Chairman & CEO||N/A||N/A||1961|
Revive Therapeutics Ltd., a specialty cannabis company, focuses on the research, development, and commercialization of novel cannabinoid-based products in Canada. Its novel cannabinoid delivery technology is to fill the medical needs for diseases and disorders, such as pain, inflammation, and wound care. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. has strategic partnership with Aximbiotech, Herman Holdings, Sanyal Biotechnology, University of South Carolina, Warf, University of Wisconsin-Madison, and Chemi Pharmaceutical Inc.; and Complete Phytochemical Solutions, LLC to advance research initiatives for psilocybin-based pharmaceutical products. The company was incorporated in 2012 and is based in Toronto, Canada.
Revive Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.